TENX

1.25010.07%
TA

Thomas A. McGauley

Principal Financial Officer & Principal Accounting Officer

Mr. Thomas A. McGauley, also known as Tom, serves as Principal Financial Officer & Principal Accounting Officer at Tenax Therapeutics, Inc. from December 2, 2024 and also served its Interim Chief Financial Officer until May 11, 2026. Mr. McGauley is responsible for the Company's accounting and finance functions. Since July 2021, Mr. McGauley has been a member of Danforth Advisors, LLC. Mr. McGauley has years of financial and executive experience. Since July 2021, he has served as a consultant to several life sciences companies through Danforth. From 2018 to 2022, Mr. McGauley was a director at CBIZ in their accounting advisory practice, where he advised public and private clients and served as the interim chief financial officer for a private life sciences company during a critical growth period. Prior to that, from 2009 to 2018, he served as the chief financial officer and a consultant to several public and private life science companies, including Galectin Therapeutics Inc. (Nasdaq: GALT), where he was the interim chief financial officer from 2012 to 2013 and the company’s financial/accounting and SEC consultant from 2009 to 2012. Prior to that, he was a senior financial executive for deCODE genetics, Inc., a former Nasdaq-listed company. Mr. McGauley began his financial career in public accounting working with several accounting firms and was most recently a manager at PricewaterhouseCoopers LLP specializing in life sciences and technology companies. Prior to that, he was an officer in the U.S. Army and later the MA National Guard, ending his military career as a captain and company commander. Mr. McGauley holds a B.S.B.A in Accounting from Stonehill College and is a Certified Public Accountant in Massachusetts.

Positions